EFFICACY AND SAFETY IN THE USE OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS AT HIGH RISK OF FRACTURE IN AN OUTPATIENT CASE SERIES FROM THE MARCHE REGION

被引：0
|
作者：
Farina, A. [1 ]
Pingiotti, E. [1 ]
Martino, G. P. [1 ]
Bitti, G. [1 ]
Angelici, S. [1 ]
机构：
[1] Osped Civile A Murri, Internal Med, Fermo, Italy
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2024年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P147
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [41] ODANACATIB ANTI-FRACTURE EFFICACY AND SAFETY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE PHASE III LONG-TERM ODANACATIB FRACTURE TRIAL
    McClung, M. R.
    Langdahl, B.
    Papapoulos, S.
    Saag, K. G.
    Adami, S.
    Bone, H. G.
    de Villiers, T.
    Kiel, D. P.
    Kung, A.
    Kumar, P.
    Lim, S. -K.
    Ling, X.
    Lippuner, K.
    Mautalen, C.
    Nakamura, T.
    Reginster, J. -Y.
    Reid, I. R.
    Rodriguez-Portales, J. A.
    Roux, C.
    Walliser, J.
    Watts, N. B.
    Zanchetta, J.
    Zerbini, C. A.
    Rybak-Feiglin, A.
    Cohn, D.
    DaSilva, C. A.
    Massaad, R.
    Santora, A.
    Scott, B. B.
    Verbruggen, N.
    Leung, A.
    Lombardi, A.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : 573 - 575
  • [42] Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
    McClung, Michael R.
    Langdahl, Bente
    Papapoulos, Socrates
    Saag, Kenneth G.
    Adami, Silvano
    Bone, Henry G.
    de Villiers, Tobias
    Kiel, Douglas P.
    Kung, Annie
    Kumar, Prasanna
    Lim, Sung-Kil
    Ling, Xu
    Lippuner, Kurt
    Mautalen, Carlos
    Nakamura, Toshitaka
    Reginster, Jean-Yves
    Reid, Ian R.
    Adolfo Rodriguez-Portales, Jose
    Roux, Christian
    Walliser, Jesus
    Watts, Nelson B.
    Zanchetta, Jose R.
    Zerbini, Cristiano A. F.
    Rybak-Feiglin, Andrea
    Cohn, Dosinda
    DaSilva, Carolyn A.
    Massaad, Rachid
    Santora, Arthur
    Scott, Boyd B.
    Verbruggen, Nadia
    Leung, Albert
    Lombardi, Antonio
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S987 - S987
  • [43] Safety and efficacy of risedronate in reducing vertebral fracture risk in elderly women with documented osteoporosis.
    Boonen, S
    Eastell, R
    Barton, IP
    McClung, MR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S370 - S370
  • [44] Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, J.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [45] Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture
    Saag, Kenneth G.
    Williams, Setareh A.
    Wang, Yamei
    Weiss, Richard J.
    Cauley, Jane A.
    CLINICAL THERAPEUTICS, 2020, 42 (06) : 1099 - +
  • [46] Targeted High-Intensity Exercise With And Without Osteoporosis Medications To Reduce Fracture Risk In Postmenopausal Women
    Kistler-Fischbacher, Melanie
    Yong, Jedidah S.
    Weeks, Benjamin K.
    Beck, Belinda R.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2021, 53 (08): : 111 - 112
  • [47] Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
    Delmas, PD
    Ensrud, KE
    Adachi, JD
    Harper, KD
    Sarkar, S
    Gennari, C
    Reginster, JY
    Pols, HAP
    Recker, RR
    Harris, ST
    Wu, WT
    Genant, HK
    Black, DM
    Eastell, R
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08): : 3609 - 3617
  • [48] ODANACATIB ANTIFRACTURE EFFICACY AND SAFETY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE PHASE III LONG-TERM ODANACATIB FRACTURE TRIAL (LOFT)
    McClung, M. R.
    Langdahl, B.
    Papapoulos, S.
    Saag, K. G.
    Adami, S.
    Bone, H. G.
    De Villiers, T.
    Kiel, D. P.
    Kung, A.
    Kumar, P. K. M.
    Lim, S. -K.
    Ling, X.
    Lippuner, K.
    Mautalen, C.
    Nakamura, T.
    Reginster, J. -Y.
    Reid, I. R.
    Rodriguez-Portales, A.
    Roux, C.
    Walliser, J.
    Watts, N. B.
    Zanchetta, J.
    Zerbini, C. A. F.
    Rybak-Feiglin, A.
    Cohn, D.
    DaSilva, C. A.
    Massaad, R.
    Santora, A. C.
    Scott, B. B.
    Kaufman, K. D.
    Verbruggen, N.
    Leung, A.
    Lombardi, A.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S35 - S36
  • [49] SELF PERCEPTION OF FRACTURE RISK, EDUCATIONAL ATTAINMENT AND ANTI-OSTEOPOROSIS MEDICATION USE AMONG POSTMENOPAUSAL WOMEN
    Litwic, A. E.
    Jameson, K. A.
    Ward, K. A.
    Cooper, C.
    Dennison, E. M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S437 - S437
  • [50] Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).
    McClung, Michael
    Langdahl, Bente
    Papapoulos, Socrates
    Saag, Kenneth
    Adami, Silvano
    Bone, Henry
    de Villiers, Tobias
    Kiel, Douglas
    Kung, Annie
    Kumar, Prasanna
    Lim, Sung-Kil
    Ling, Xu
    Lippuner, Kurt
    Mautalen, Carlos
    Nakamura, Toshitaka
    Reginster, Jean-Yves
    Reid, Ian
    Rodriguez Portales, Jose
    Roux, Christian
    Walliser, Jesus
    Watts, Nelson
    Ruben Zanchetta, Jose
    Zerbini, Cristiano
    Rybak-Feiglin, Andrea
    Cohn, Dosinda
    DaSilva, Carolyn
    Massaad, Rachid
    Santora, Arthur
    Scott, Boyd
    Verbruggen, Nadia
    Leung, Albert
    Lombardi, Antonio
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S51 - S51
12345